Drugs / AZD6563
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06147063 | Nov 2023 → Apr 2024 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-08 | AstraZeneca | Results AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025 astrazeneca.com ↗
Data on AZD6563, an investigational novel COVID-19 mRNA vaccine-like particle (VLP) vaccine, demonstrating that a low dose may elicit equivalent cell-mediated immunity to a licensed mRNA vaccine will also be shared. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-08 | AstraZeneca | AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025 astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06147063 ↗ |
| Modality | Vaccine | “AZD9838 and AZD6563 Vaccine” NCT06147063 ↗ |